J C Dubus1, C Marguet, A Deschildre, L Mely, P Le Roux, J Brouard, L Huiart. 1. Services de Pédiatrie, CHU Timone-Enfants, Marseille, Hôpital Charles Nicolle (Rouen), Hôpital Jeanne de Flandres (Lille), Hôpital du Havre (Le Havre), CH Côte de Nâcre (Caen), INSERM U379, Institut Paoli-Calmette, Marseille, France.
Abstract
BACKGROUND: The objective was to investigate the local side-effects of inhaled corticosteroids (ICS) in daily life in asthmatic children, particularly the younger ones, by an observational prospective cross-sectional cohort study. METHODS: Asthmatic children (n=639, 75.9+/-48.9 months, 61.3% boys), treated with beclomethasone dipropionate (BDP) (721.0+/-287.3 microg per day) or budesonide (BUD) (835.5+/-684.9 microg per day) for at least 1 month, were recruited at the time of a scheduled visit. Local side-effects were researched by questionnaire (cough during inhalation, hoarseness, dysphonia, and thirsty feeling) and clinical examination (perioral dermatitis, oral candidiasis, and tongue hypertrophy). RESULTS: Exactly 63.3% of the children aged under 6 years and 59.5% of the older ones reported one local side-effect. Cough (39.7%) was dependent on young age, use of BDP, and mainly use of spacer device, with an OR of 4.7 (95% CI: 2.7-8.2). Thirsty feeling (21.9%) and hoarseness (14.1%) occurred in children using ICS and long-acting beta2-agonists. Dysphonia (11.1%) was favored by high doses of BDP and BUD, and by inhalation from spacer devices or nebulizers. No factor favored oral candidiasis (10.7%). Perioral dermatitis (2.9%) and tongue hypertrophy (0.1%) were associated with nebulization. CONCLUSION: Local side-effects of ICS are common in asthmatic children of all ages, and the device used constitutes the most influential factor.
BACKGROUND: The objective was to investigate the local side-effects of inhaled corticosteroids (ICS) in daily life in asthmatic children, particularly the younger ones, by an observational prospective cross-sectional cohort study. METHODS: Asthmatic children (n=639, 75.9+/-48.9 months, 61.3% boys), treated with beclomethasone dipropionate (BDP) (721.0+/-287.3 microg per day) or budesonide (BUD) (835.5+/-684.9 microg per day) for at least 1 month, were recruited at the time of a scheduled visit. Local side-effects were researched by questionnaire (cough during inhalation, hoarseness, dysphonia, and thirsty feeling) and clinical examination (perioral dermatitis, oral candidiasis, and tongue hypertrophy). RESULTS: Exactly 63.3% of the children aged under 6 years and 59.5% of the older ones reported one local side-effect. Cough (39.7%) was dependent on young age, use of BDP, and mainly use of spacer device, with an OR of 4.7 (95% CI: 2.7-8.2). Thirsty feeling (21.9%) and hoarseness (14.1%) occurred in children using ICS and long-acting beta2-agonists. Dysphonia (11.1%) was favored by high doses of BDP and BUD, and by inhalation from spacer devices or nebulizers. No factor favored oral candidiasis (10.7%). Perioral dermatitis (2.9%) and tongue hypertrophy (0.1%) were associated with nebulization. CONCLUSION: Local side-effects of ICS are common in asthmatic children of all ages, and the device used constitutes the most influential factor.
Authors: Bernardino Alcázar Navarrete; Pedro José Romero Palacios; Antonio Aguilar-Salvatierra; Javier Guardia; Gerardo Gómez-Moreno Journal: Clin Drug Investig Date: 2015-09 Impact factor: 2.859
Authors: T W de Vries; J J de Langen-Wouterse; E van Puijenbroek; E J Duiverman; L T W de Jong-Van den Berg Journal: Eur J Clin Pharmacol Date: 2006-04-01 Impact factor: 2.953
Authors: Mohamed S Al-Moamary; Mohamed S Al-Hajjaj; Majdy M Idrees; Mohamed O Zeitouni; Mohammed O Alanezi; Hamdan H Al-Jahdali; Maha Al Dabbagh Journal: Ann Thorac Med Date: 2009-10 Impact factor: 2.219